Connect With Us:
ADAP Long-Acting Injectables Patient Advisory Committee:
Quick Links: Committee Meetings | Committee Policy Assets | Committee Resources | Disclosures
Committee Members
Click here to download the member directory.
ADAP Advocacy is currently recruiting patients and public health stakeholders to serve on its ADAP Long-Acting Injectables Patient Advisory Committee Membership. CLICK HERE to apply for membership.
Committee Meetings
April 28, 2025
Click on the links to download the following meeting materials:
Committee Policy Assets
AIDS Drug Assistance Programs
- HIV LONG-ACTING INJECTABLES: Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis - (June 2024)
- HIV LONG-ACTING AGENTS: Policy Considerations for Injectable Therapies under the Ryan White HIV/AIDS Program & State AIDS Drug Assistance Programs - (August 2022)
Committee Resources
U.S. Food & Drug Administration (FDA)
- FDA Approves Sunlenca for Adults With Resistant HIV - (December 2022)*
- FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention - (December 2021)
- FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection - (January 2021)
- FDA approves new HIV treatment for patients who have limited treatment options - (March 2018)
- FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients - (November 2010)
* Press statement no longer available on FDA's website
HIV+Hep Policy Institute
O’Neill Institute for National and Global Health Law at Georgetown University
Positively Aware Magazine
- Guide to Long-Acting Injectables for HIV - (August 1, 2024)
- Attitudes and Access: Survey Results on Long-Acting Injectables for HIV - (June 26, 2024)
Disclosures
This project is funded by the following corporate entities:
Gilead Sciences, Merck, and ViiV Healthcare.